ADMA Biologics

Moat components and scores: Intangible assets 70. ASCENIV and BIVIGAM are FDA‑approved biologics with brand acceptance in PI, and ASCENIV is protected by patented donor screening and plasma pooling methodology referenced in company materials.

These are helpful but not impregnable like a composition‑of‑matter drug patent. (Weight 20 percent) Switching costs 75. Once stabilized, PI patients and sites of care are reluctant to switch IVIG brands due to tolerability, reimbursement, and formulary dynamics, creating moderate switching frictions rather than absolute lock‑in. (Weight 30 percent) Network effects 20. No meaningful network effects. (Weight 10 percent) Cost advantages 65. Yield‑enhanced production and a self‑supply plasma network support structurally better unit economics than in ADMA’s past.

FDA lot release of yield‑enhanced batches began in late 2025, and Q1 2026 margin reached about 71 percent. (Weight 20 percent) Efficient scale 80. Plasma fractionation is capital and compliance intensive, with few scaled players and high FDA oversight.

ADMA operates a Boca Raton facility and a network of FDA‑licensed plasma centers concentrated in the Southeast, with enough internal supply to support its portfolio. (Weight 20 percent) Weighted together these support a durable but not indestructible moat anchored in regulatory barriers, quality systems, and growing production know‑how.

Key erosion risks: standard IG price resets; regulatory actions at plants or centers; and larger competitors exerting purchasing and contracting power.

Evidence of pricing and mix strength comes from expanding gross margins and ASCENIV’s premium positioning. In Q1 2026, total revenue was essentially flat year over year at 114.5 million, but gross margin expanded to about 71 percent on richer mix and yields.

Management also noted persistent pressure in standard IG, which weighed on BIVIGAM volumes and likely pricing. The recent pediatric label expansion increases ASCENIV’s addressable market and should sustain premium positioning. Latent pricing power is therefore concentrated in ASCENIV rather than in the commoditizing portions of standard IG.

Key watch items: payer dynamics, site‑of‑care mix, and competitor supply ramp.

Immunoglobulin demand for PI and related conditions tends to be steady and growing mid‑single to low‑double digits over long periods, which lends itself to recurring revenue characteristics.

For ADMA, TTM revenue through March 31, 2026 is roughly 510 million using FY 2025 results adjusted for Q1 2026 and Q1 2025, with Q1 2026 revenue flat year over year.

While top line predictability is moderated by standard IG pricing cycles and channel inventory normalization, the cash generation profile is improving due to rising ASCENIV mix and manufacturing yields.

Regulatory or manufacturing events remain the main sources of unpredictability, but near‑term visibility is supported by FDA‑approved products and expanded labeling. Geographic exposure is primarily U.S., a favorable jurisdiction from a legal and IP standpoint.

At March 31, 2026, cash and equivalents were about 138 million and total debt was about 197 million, implying net debt near 59 million. Debt rose in part due to an accelerated share repurchase. The interest rate on the JPM facilities was approximately 6.17 percent, and the company reported compliance with covenants.

Trailing twelve month operating cash flow is estimated near 128 million and TTM free cash flow near 108 million after capital expenditures, which compares favorably to net debt and suggests solid coverage. Liquidity and self‑funding capacity are adequate, with working capital of roughly 438 million at quarter end.

Risks: a sudden demand shock or regulatory issue could elevate inventories or receivables, and higher rates would modestly lift interest expense.

Management is prioritizing internal reinvestment in yield‑enhanced production and maintaining a vertically integrated plasma supply, which we view favorably.

In 2025 ADMA initiated a 500 million share repurchase authorization and executed a 125 million accelerated share repurchase in Q1 2026, receiving about 6.4 million shares initially and buying back roughly 6.75 million shares in the quarter in total.

While repurchases can be value accretive, the concurrent draw on the revolver lifted gross debt from about 72 million at year end 2025 to about 197 million at March 31, 2026, which raises the execution bar and reduces flexibility if end‑market conditions weaken.

Stock‑based compensation was meaningful but not excessive for a growing commercial‑stage biotech. We would prefer buybacks be paced with free cash flow and after reserving for working capital variability.

Founder‑CEO Adam Grossman has led ADMA through the transition from contract manufacturing issues several years ago to a profitable, vertically integrated operator.

The CFO transition in February 2026 from Brad Tade to Terry Kohler appears orderly, with Tade supporting through July 2026. Management acted quickly to rebut March 2026 short‑seller allegations with detailed disclosures and emphasized unqualified audit opinions for 2024 and 2025. We view the team as capable and execution‑oriented, with a bias toward operational improvements and measured portfolio expansion.

Watch items include consistency of disclosures around working capital and distribution channel dynamics, and continued delivery on guidance after the 2026 reset.